Christina Therkildsen
Research group leader
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Supplementary Table S1. Summary of clinical information. Supplementary Table S2. Summary of sample characteristics. Supplementary Table S3. Summary of whole-genome sequencing and fragment analyses. Supplementary Table S4. Summary of protein analyses. Supplementary Table S5. Summary of machine learning models and scores. Supplementary Table S6. Summary of performance for ovarian cancer detection.
Year:
2025
Ovarian cancer is a leading cause of death for women worldwide, in part due to ineffective screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker [cancer antigen 125 (CA-125) and human epididymis protein 4 (HE4)] analyses to evaluate 591 women with ovarian cancer, with benign adnexal masses, or without ovarian lesions. Using a machine learning model with the combined features, we detected ovarian cancer with specificity >99% and sensitivities of 72%, 69%, 87%, and 100% for stages I to IV, respectively. At the same specificity, CA-125 alone detected 34%, 62%, 63%, and 100%, and HE4 alone detected 28%, 27%, 67%, and 100% of ovarian cancers for stages I to IV, respectively. Our approach differentiated benign masses from ovarian cancers with high accuracy (AUC = 0.88, 95% confidence interval, 0.83–0.92). These results were validated in an independent population. These findings show that integrated cfDNA fragmentome and protein analyses detect ovarian cancers with high performance, enabling a new accessible approach for noninvasive ovarian cancer screening and diagnostic evaluation. Significance: There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that evaluates cfDNA fragmentomes and protein biomarkers to detect ovarian cancer.
Year:
2025
Supplementary Figure S1. Evaluation of screening model DELFI-Pro scores and comorbidities in individuals without cancer. Supplementary Figure S2. DELFI-Pro score evaluation in available clinical characteristics of patients with cancer. Supplementary Figure S3. Stability analysis across fold repeats and collection source. Supplementary Figure S4. Detection of ovarian cancer subtypes using DELFI-Pro screening model. Supplementary Figure S5. ROC analyses of asymptomatic individuals in the using screening or diagnostic models in the Discovery Cohort. Supplementary Figure S6. Performance of ichorCNA and median cfDNA fragment lengths in the Discovery Cohorts. Supplementary Figure S7. Detection of ovarian cancer subtypes using DELFI-Pro at high specificity. Supplementary Figure S8. Genome-wide fragmentation profiles are altered in patients in the Validation Cohort with ovarian cancer. Supplementary Figure S9. Analyses of chromosomal changes in Discovery and Validation cohorts. Supplementary Figure S10. Performance of DELFI-Pro for detection of ovarian cancer in the Validation Cohort. Supplementary Figure S11. Correlation of rank ordered DELFI-Pro scores for the Screening and Diagnostic models. Supplementary Figure S12. Assessment of DELFI-Pro in women with benign lesions. Supplementary Figure S13. Performance of DELFI-Pro for distinguishing ovarian cancer from benign masses. Supplementary Figure S14. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses. Supplementary Figure S15. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses in Validation Cohort. Supplementary Figure S16. Evaluation of overall tumor burden using the sum of reported lesion diameters. Supplementary Figure S17. Evaluation of CA1-25 and HE4 blood concentrations measured at different centers.
Year:
2025
The fragmentation patterns of whole genome sequenced cell-free DNA are promising features for tumor-agnostic cancer detection. However, systematic biases challenge their cross-cohort generalization. We introduce LIONHEART, a novel, open source cancer detection method specifically optimized to generalize across datasets. The method correlates bias-corrected cfDNA fragment coverage across the genome with the locations of accessible chromatin regions from 898 cell and tissue type features. We use these correlations to detect changes in the cell-free DNA cell type composition caused by cancer. We test LIONHEART on nine datasets and fourteen cancer types (1106 non-cancer controls, 1449 cancers) obtained from different studies and show that it can distinguish cancer samples from non-cancer controls across cohorts with ROC AUC scores ranging from 0.62-0.95 (mean = 0.83, std = 0.12). We further validate the method on an external dataset, achieving a ROC AUC of 0.917.
Year:
2024
Collaborators (22)
Mads Ryø Jochumsen
Aarhus University
Jillian Phallen
Johns Hopkins University School of Medicine
Tenna Henriksen
VIP, Tenure Track Assistant Professor
Aarhus University
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Gerrit Meijer
Professor of Oncologic Pathology
University Medical Center Groningen
Dimitrios Mathios
Assistant Professor
Washington University in St. Louis
Victor E. Velculescu
Assistant/Associate/Professor of Oncology and Pathology
Johns Hopkins University School of Medicine
Marijana Nesic
Aarhus University Hospital
Lars Dyrskjøt
Aarhus University Hospital
Anders Jacobsen Skanderup
Principal Investigator
Genome Institute of Singapore
Amanda Frydendahl
Aarhus University
Karina Dalsgaard Sørensen
VIP, Professor
Aarhus University
Dennis J. Slamon
University of California, Los Angeles
Michael Borre
Chair professor
Aarhus University Hospital
Jenna Canzoniero
Assistant Professor - Women's Malignancies Program
Johns Hopkins University School of Medicine
Claus Lindbjerg Andersen
VIP, Professor
Aarhus University
Beatriz Carvalho
Senior scientist
The Netherlands Cancer Institute
Iver Kristiansen Nordentoft
Senior Researcher
Aarhus Universitetshospital
Ronny Drapkin
Franklin Payne Professor of Pathology in Obstetrics and Gynecology
University of Pennsylvania
Søren Besenbacher
Associate Professor
Aarhus University
Robert B Scharpf
Associate Professor
Johns Hopkins University School of Medicine
Mads Heilskov Rasmussen
VIP, Associate Professor
Aarhus University
Make your next move.
Prepare your application
Review drafts before you send them.